This investment reinforces Beiersdorf’s commitment to scientific innovation in skin care, positioning the company at the forefront of biotechnology-driven cosmetic solutions.
USA – Beiersdorf has teamed up with Vincere Biosciences, an American-based company, a biotechnology firm focused on developing innovative treatments for age-related diseases, in a groundbreaking investment aimed at revolutionizing skin health and ageing.
The investment aims to develop innovative skin care solutions by leveraging scientific advancements in cellular health and rejuvenation.
This partnership brings together Beiersdorf’s extensive expertise in active ingredient cosmetics and Vincere Biosciences’ pioneering research in mitochondrial health.
The collaboration focuses on mitophagy, the process of clearing damaged mitochondria from cells, to enhance skin renewal and longevity.
Dr. Gitta Neufang, Chief R&D Officer at Beiersdorf, stated, “With this investment, we underline our commitment and our leading role as skin experts and innovators in the field of skin care.”
“This strategic partnership will allow us to uncover new regulatory mechanisms in skin biology that are key to advancing cosmetic solutions.”
Beiersdorf, known for its pioneering research in coenzyme Q10, is set to integrate its expertise with Vincere Biosciences’ work on USP30, an enzyme that inhibits mitochondrial cleanup.
In addition, the partnership seeks to enhance cellular renewal, potentially benefiting not only skin health but also age-related diseases such as Parkinson’s, by targeting USP30.
Dr. Spring Behrouz, CEO of Vincere Biosciences. “Mitophagy is one of the body’s most powerful tools for cellular renewal.”
“This collaboration also highlights the broader potential of Vincere’s USP30 pipeline across age-related disorders beyond our primary focus on halting Parkinson’s disease.”
This investment reinforces Beiersdorf’s commitment to scientific innovation in skin care, positioning the company at the forefront of biotechnology-driven cosmetic solutions.
Recently, Beiersdorf reported positive financial performance for the first quarter of fiscal year 2025, posting €2.7 billion(USD 3.08 billion) in sales and a 3.6% increase in organic sales.
The Consumer segment achieved a 2.3% organic sales growth, driven by strong results from its Derma brands, Eucerin and Aquaphor, which reported double-digit growth of 11.4%.
NIVEA also showed resilience with a 2.5% sales increase, supported by innovations in skincare categories and strong growth in North America.
Chantecaille achieved a remarkable 15.9% increase in organic sales, fueled by its continued expansion in mainland China and broader Asian markets.
However, La Prairie experienced a 17.5% decline in sales due to ongoing challenges in the Chinese market and the travel retail sector.
Looking ahead, Beiersdorf has reaffirmed its full-year 2025 outlook, projecting organic sales growth between 4% and 6% for the Group and its Consumer Business Segment.
The company also anticipates a slight increase in its adjusted EBIT margin to 16%, up from 13.9% in the previous year.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.